An insight on hyaluronic acid in drug targeting and drug delivery

Yadav, Awesh K.; Mishra, Pradeep; Agrawal, Govind P.

doi:10.1080/10611860701794296

Cited by 111 publications

(66 citation statements)

References 89 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reviews have previously discussed the advantages of HA as a drug carrier and a targeting ligand for cancer, as well as other pathologies (23)(24)(25)(26)(27)(28). Direct intratumoral delivery systems have significant potential advantages due to providing higher drug concentration at the target site compared with systemic routes and circumvention of the various physiological barriers to tumor drug delivery including the high interstitial pressure common to most solid tumors (29).…”

Section: Discussionmentioning

confidence: 99%

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations

et al. 2009

View full text Add to dashboard Cite

Abstract. In the current study, novel paclitaxel-loaded cross-linked hyaluronan nanoparticles were engineered for the local delivery of paclitaxel as a prototype drug for cancer therapy. The nanoparticles were prepared using a desolvation method with polymer cross-linking. In vitro cytotoxicity studies demonstrated that less than 75% of the MDA-MB-231 and ZR-75-1 breast cancer cells were viable after 2-day exposure to paclitaxel-loaded hyaluronan nanoparticles or free paclitaxel, regardless of the dose. These results suggest that hyaluronan nanoparticles maintain the pharmacological activity of paclitaxel and efficiently deliver it to the cells. Furthermore, in vivo administration of the drug-loaded nanoparticles via direct intratumoral injection to 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumor in female rats was studied. The paclitaxel-loaded nanoparticles treated group showed effective inhibition of tumor growth in all treated rats. Interestingly, there was one case of complete remission of tumor nodule and two cases of persistent reduction of tumor size that was observed on subsequent days. In the case of free paclitaxel-treated group, the mean tumor volume increased almost linearly (R 2 =0.93) with time to a size that was 4.9-fold larger than the baseline volume at 57 days post-drug administration. Intratumoral administration of paclitaxel-loaded hyaluronan nanoparticles could be a promising treatment modality for solid mammary tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Thus, a wide array of different chemotherapeutic reagents can be chemically conjugated to HA. A review of the chemical derivatization of HA and the potential applications of HA to disease treatment is beyond the scope of this chapter but has been recently reviewed [63,64]. In brief, previous investigations in vitro showed that a taxol-HA bioconjugate was cytotoxic to a panel of tumor cell lines (breast, colon and ovarian) but not human fibroblasts [65].…”

Section: Drug Deliverymentioning

confidence: 99%

Hyaluronan Endocytosis: Mechanisms of Uptake and Biological Functions

Racine¹,

Mummert²

2012

Molecular Regulation of Endocytosis

View full text Add to dashboard Cite

“…Although HMW-HA (Ͼ1 ϫ 10 6 ) is produced endogenously and is an integral component of the ECM, synovial fluid, and vitreous humor, recent attention has been focused on the use of exogenously administered HMW-HA in a variety of diseases, including lung disease (15,40,68,156). In vitro, exogenous administration of HMW-HA inhibits ROS, nitrotyrosine, and inflammatory cytokine production and also promotes immune tolerance (9,88,157).…”

Section: Protective Effects Of Exogenous Administration Of Hmw-hamentioning

confidence: 99%

Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology

Lennon

Singleton

2011

American Journal of Physiology-Lung Cellular and Molecular Phys

View full text Add to dashboard Cite

Hyaluronan (HA) has diverse functions in normal lung homeostasis and pulmonary disease. HA constitutes the major glycosaminoglycan in lung tissue, with HA degradation products, produced by hyaluronidase enzymes and reactive oxygen species, being implicated in several lung diseases, including acute lung injury, asthma, chronic obstructive pulmonary disease, and pulmonary hypertension. The differential activities of HA and its degradation products are due, in part, to regulation of multiple HA-binding proteins, including cluster of differentiation 44 (CD44), Toll-like receptor 4 (TLR4), HA-binding protein 2 (HABP2), and receptor for HA-mediated motility (RHAMM). Recent research indicates that exogenous administration of high-molecular-weight HA can serve as a novel therapeutic intervention for lung diseases, including lipopolysaccharide (LPS)-induced acute lung injury, sepsis/ventilator-induced lung injury, and airway hyperreactivity. This review focuses on the regulatory role of HA and HA-binding proteins in lung pathology and discusses the capacity of HA to augment and inhibit various lung diseases.

show abstract

An insight on hyaluronic acid in drug targeting and drug delivery

Cited by 111 publications

References 89 publications

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations

Hyaluronan Endocytosis: Mechanisms of Uptake and Biological Functions

Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology

Contact Info

Product

Resources

About